Overview
A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-03-31
2025-03-31
Target enrollment:
Participant gender: